Clinical Trial Update: A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pyrotinib in combination with trastuzumab and docetaxel for metastatic HER2-positive breast cancer is underway, with status not specifi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: UNKNOWN